Device to Narrow the Coronary Sinus Effective for Refractory Angina

Implantation of the device improved symptoms and quality of life in a small study of patients ineligible for revascularization.

Patients with refractory angina not amenable to revascularization have few options. To test a new device designed to improve symptoms in such patients, investigators conducted a manufacturer-sponsored, phase II, randomized, sham-controlled trial of an hourglass-shaped, metal-mesh “Reducer” that is inserted in the coronary sinus to create a pressure gradient that theoretically redistributes blood toward ischemic myocardium.

The study involved 104 patients (mean age, 68; 81% men) with Canadian Cardiovascular Society (CCS) class III or IV angina despite maximal medical therapy; the patients had evidence of reversible ischemia and were not eligible for coronary revascularization. Patients were randomized to undergo implantation of the device or …

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)